ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer
- 16 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 182 (1), 85-96
- https://doi.org/10.1007/s10549-020-05677-4
Abstract
Purpose The efficacy of nab-paclitaxel in patients with metastatic breast cancer (MBC) has been demonstrated in randomized clinical trials. However, real-world evidence on effectiveness remains limited. Patients and methods The primary objective of this multicenter prospective study was to assess the overall response rate (ORR) of patients with MBC treated with nab-paclitaxel. Secondary objectives included progression-free survival (PFS), overall survival (OS) and quality of life, assessed with the Functional Assessment of Cancer Therapy-Breast (FACT-B) instrument. Results Eligible patients (N = 150; 36% with de novo MBC presentation) with a median age of 64.5 years were enrolled (86% were ER+, 33.3% (50/150) were ≥ 70 years of age and 53% were treated in the third or later line of treatment). A median of 6 cycles were administered but 26% of patients required dose reduction due to toxicity. The ORR was 26.7% [95% confidence interval (CI) 19.6–33.7], the median PFS was 6.2 months (95% CI 5.2–7.3), and the median OS 21.1 months (95% CI 17.2-not estimable). There was no statistical significant difference in the median PFS of patients < and ≥ 70 years of age. The patients’ baseline FACT-B total score remained unchanged. The serious and non-serious adverse event incidence rates were 13% and 48%, respectively. Conclusions This prospective study provides further evidence on quality of life, efficacy, and safety of nab-paclitaxel in patients with MBC and sheds more light in special subpopulations such as the elderly and those treated beyond the second line.Keywords
Funding Information
- Genesis Pharma
This publication has 21 references indexed in Scilit:
- Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patientsDrug Design, Development and Therapy, 2015
- Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United StatesJNCI Journal of the National Cancer Institute, 2015
- Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of lifeDrug Design, Development and Therapy, 2015
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular SubtypesClinical Cancer Research, 2013
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2012
- Taxanes for the Treatment of Metastatic Breast CancerBreast Cancer: Basic and Clinical Research, 2012
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast CancerJournal of Clinical Oncology, 2005
- Are Older French Patients As Willing As Older American Patients to Undertake Chemotherapy?Journal of Clinical Oncology, 2003
- Molecular portraits of human breast tumoursNature, 2000